List of Excipients in Branded Drug CYCLOBENZAPRINE HCI

Generic Drugs Containing CYCLOBENZAPRINE HCI

Company	Ingredient	NDC	Excipient
DIRECTRX	cyclobenzaprine hci	61919-681	HYDROXYPROPYL CELLULOSE
DIRECTRX	cyclobenzaprine hci	61919-681	HYPROMELLOSE
DIRECTRX	cyclobenzaprine hci	61919-681	LACTOSE MONOHYDRATE
DIRECTRX	cyclobenzaprine hci	61919-681	MAGNESIUM STEARATE
DIRECTRX	cyclobenzaprine hci	61919-681	POLYETHYLENE GLYCOL
DIRECTRX	cyclobenzaprine hci	61919-681	STARCH, CORN
DIRECTRX	cyclobenzaprine hci	61919-681	TALC

What are the Most Frequently-Used Excipients in CYCLOBENZAPRINE HCI?

# Of NDCs	Excipient
1	HYDROXYPROPYL CELLULOSE
1	HYPROMELLOSE
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
1	STARCH, CORN
1	TALC

Cyclobenzaprine HCl Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Cyclobenzaprine HCl is a mature, genericized skeletal-muscle relaxant with established immediate-release and extended-release dosage forms. The strongest commercial opportunities are differentiated oral products that improve swallowing, onset control, adherence, dose flexibility, or tolerability without materially increasing regulatory complexity. Excipient selection should focus on moisture protection, dissolution control, taste masking, tablet robustness, and compatibility with central-nervous-system safety labeling.

What dosage forms and strengths are available for cyclobenzaprine HCl?

Cyclobenzaprine HCl is marketed primarily as immediate-release tablets and extended-release capsules. The immediate-release product is generally dosed three times daily, while the extended-release product is dosed once daily.

Product type	Typical strengths	Administration profile	Commercial status
Immediate-release tablet	5 mg, 7.5 mg, 10 mg	Usually three times daily	Generic and branded products
Extended-release capsule	15 mg, 30 mg	Once daily	Generic products; Amrix reference product history
Oral solution or suspension	Limited availability	Flexible dosing	Potential differentiated opportunity
Orally disintegrating tablet	Limited mainstream availability	Rapid oral disintegration	Potential lifecycle opportunity
Sprinkle or multiparticulate capsule	Limited availability	Alternative swallowing profile	Potential lifecycle opportunity

Cyclobenzaprine HCl is approved for short-term treatment of acute painful musculoskeletal conditions as an adjunct to rest and physical therapy. The FDA labeling generally limits treatment to two or three weeks because controlled evidence for longer use is limited.[1,2]

The molecule is structurally related to tricyclic antidepressants. Its labeling includes warnings involving anticholinergic effects, sedation, serotonin syndrome risk when combined with serotonergic drugs, and contraindications involving monoamine oxidase inhibitors and certain cardiovascular conditions.[1,2]

What excipients are used in cyclobenzaprine HCl tablets and capsules?

Excipients vary by manufacturer, strength, color system, manufacturing process, and regulatory filing. Common functional categories include:

Excipient function	Typical candidates	Strategic purpose
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate, mannitol	Controls tablet weight and content uniformity
Binder	Povidone, copovidone, pregelatinized starch, hypromellose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports immediate drug release
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces tooling friction
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose, polyvinyl alcohol	Protects the tablet and controls appearance
Plasticizer	Polyethylene glycol, triethyl citrate	Improves coating flexibility
Opacifier and colorant	Titanium dioxide, iron oxides, approved dyes	Product identification and light protection
Release-control polymer	Hypromellose, ethylcellulose, methacrylate copolymers	Controls extended release
Taste-masking polymer	Ethylcellulose, methacrylate polymers, shellac-type systems	Reduces bitterness in liquid and orally disintegrating products
Suspension stabilizer	Xanthan gum, hydroxyethylcellulose, sodium carboxymethylcellulose	Maintains dose uniformity in liquids

Immediate-release tablets generally benefit from conventional excipient systems because cyclobenzaprine products have low dose strength and established dissolution behavior. The main development risk is not the number of excipients but the effect of formulation changes on dissolution, content uniformity, tablet hardness, and disintegration.

Product-specific inactive ingredients should be confirmed against the applicable DailyMed label and FDA-approved product labeling because generic formulations are not compositionally identical.[3]

Which excipient strategies are most commercially attractive?

Immediate-release tablets with improved swallowability

The largest near-term market is the conventional immediate-release tablet. Differentiation can come from:

• Smaller tablets at equivalent strength
• Lower-force compression
• Rapid disintegration
• Film coatings with improved slipperiness
• Scored 5 mg, 7.5 mg, and 10 mg presentations
• Lactose-free or dye-free versions
• Products suitable for patients with medication sensitivities

Microcrystalline cellulose, mannitol, copovidone, crospovidone, and sodium stearyl fumarate can support direct-compression or dry-granulation platforms. A lower tablet mass can improve swallowing but requires careful control of blend uniformity because the active dose is small.

Cyclobenzaprine HCl is pharmacologically active at low milligram strengths. Content-uniformity performance, rather than total drug loading, is therefore central to formulation design.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia, acute pain, or difficulty swallowing during muscle spasm episodes. Mannitol can provide a cooling mouthfeel and acceptable bulk. Crospovidone can support rapid disintegration, while sucralose, acesulfame potassium, flavor systems, and polymeric taste-masking coatings can reduce bitterness.

The principal technical issue is taste. Cyclobenzaprine HCl is not an ideal candidate for an unmasked fast-dissolving dosage form if the drug releases immediately in the mouth. A coated drug-particle approach may be preferable to simple flavor addition.

Potential approaches include:

1. Fluid-bed coating of micronized drug particles.
2. Ion-exchange resin complexation.
3. Lipid or polymeric barriers.
4. Drug-loaded granules incorporated into an ODT matrix.
5. Effervescent or porous tablet technologies.

The product must retain rapid disintegration while preventing early drug release in the oral cavity. In vitro dissolution should be evaluated under both compendial conditions and simulated saliva exposure.

Oral liquid and suspension products

A liquid formulation could provide commercial value for patients unable to swallow tablets and for dose titration. The formulation must address:

• Aqueous solubility and pH stability
• Chemical stability over the proposed shelf life
• Preservative effectiveness
• Sedimentation or caking if a suspension is used
• Palatability
• Measuring-device accuracy
• Child-resistant packaging
• Alcohol and sugar content

An oral solution has a simpler dose-delivery concept but can expose the drug to hydrolysis, oxidation, light, or microbial risk. A suspension may improve stability or taste masking but introduces redispersibility and dose-uniformity requirements.

Cyclobenzaprine products are not generally positioned for pediatric use, so a liquid product would more likely target adults with swallowing limitations or controlled dose administration rather than children.

Extended-release multiparticulate systems

Extended-release cyclobenzaprine creates the clearest formulation-based differentiation because the reference product established once-daily dosing. Multiparticulate capsules, coated pellets, mini-tablets, or matrix systems may provide:

• More reproducible gastrointestinal distribution
• Reduced sensitivity to single-unit failure
• Tunable release over several hours
• Sprinkle administration potential
• Flexibility in combining immediate-release and delayed-release fractions

Ethylcellulose, hypromellose, methacrylate copolymers, and pore-forming excipients can be used to control release. The formulation must be evaluated for alcohol-induced dose dumping, food effects, storage humidity, and interbatch coating variability.

A generic extended-release product must demonstrate bioequivalence using FDA-accepted pharmacokinetic endpoints. Release-profile similarity alone is insufficient for approval where the regulatory pathway requires in vivo comparison.

What formulation patents could protect cyclobenzaprine products?

Patent value for cyclobenzaprine is concentrated in formulation and delivery claims rather than the basic active ingredient. The original composition-of-matter protection for cyclobenzaprine is long expired. Commercially relevant claim categories include:

• Extended-release pellets or capsules
• Specific dissolution profiles
• Multiparticulate systems
• Immediate-release and sustained-release combinations
• Taste-masked particles
• Orally disintegrating tablets
• Liquid formulations with defined pH and stabilizer systems
• Manufacturing processes for coated beads or matrix tablets
• Methods of treating acute muscle spasm with defined dosing regimens

The Amrix extended-release product was associated with formulation-related intellectual property and FDA Orange Book listings during its branded commercialization period. The commercial importance of those patents has declined as listed patents expired or became less relevant to current generic entry. Current Orange Book status must be assessed by product, patent number, expiration date, and any pediatric exclusivity adjustment rather than by the historical brand name alone.[4]

How strong is the current patent estate?

The base active ingredient has weak residual exclusivity value because it is an old small molecule with broad generic availability. A new patent estate could still have value if it claims a technically narrow formulation that produces a clinically meaningful pharmacokinetic or administration advantage.

The strongest potential claims would combine:

• A defined particle or pellet architecture
• A reproducible release profile
• A clinically relevant once-daily exposure pattern
• Improved food-effect performance
• Reduced peak-related sedation
• A manufacturing process that is difficult to design around

Weak claims would rely only on routine excipient substitutions, broad lists of polymers, or conventional tablet compositions without a measurable performance advantage.

What is the FDA and Orange Book status of cyclobenzaprine HCl?

Cyclobenzaprine HCl is an FDA-approved prescription drug. Immediate-release tablets are approved in multiple strengths, and extended-release capsules have been approved under the Amrix product family and subsequent generic applications.[1,2]

The FDA Orange Book identifies approved products, reference-listed drugs, therapeutic equivalence evaluations, and patent or exclusivity information where applicable.[4] Because cyclobenzaprine is a mature generic product, the main regulatory pathways are:

• Abbreviated New Drug Application for an immediate-release generic
• Abbreviated New Drug Application for an extended-release generic
• 505(b)(2) application for a materially differentiated dosage form or delivery system
• New drug application or reformulated product pathway for a novel clinical profile

A conventional immediate-release tablet with the same strength and route generally offers the lowest regulatory risk. A new ODT, liquid, sprinkle product, or modified-release system may require additional pharmacokinetic, food-effect, in vitro, and clinical bridging work.

When does cyclobenzaprine lose exclusivity?

Cyclobenzaprine's core small-molecule exclusivity has already expired. Current market protection depends on product-specific formulation patents, regulatory exclusivity, trademarks, manufacturing scale, distribution contracts, and therapeutic-equivalence status.

Protection type	Current commercial relevance
Composition-of-matter patent	Expired
Conventional immediate-release generic entry	Established
Brand trademark protection	Limited to branding and trade dress
Extended-release formulation patents	Historically important; product-specific review required
New dosage-form patents	Potentially available for new development
Pediatric exclusivity	Requires product-specific FDA confirmation
Orphan exclusivity	Not applicable to standard cyclobenzaprine use

A Paragraph IV challenge is most relevant when an ANDA applicant seeks approval before expiration of a listed formulation patent. For current immediate-release products, the principal risk is generally not a new Paragraph IV event but price erosion from multiple approved suppliers. For a protected new formulation, Paragraph IV litigation could arise if the applicant certifies that listed patents are invalid, unenforceable, or not infringed under the Hatch-Waxman framework.[5]

Which companies are challenging cyclobenzaprine patents?

Cyclobenzaprine has been subject to the normal generic competition associated with a mature prescription product. Specific current Paragraph IV challengers, litigation defendants, and settlement terms must be tied to the relevant Orange Book-listed patent and FDA application. Historical generic entry does not establish that an active patent challenge remains pending.

For commercial diligence, the relevant records are:

1. FDA Orange Book patent listings.
2. FDA Paragraph IV certification notifications.
3. Federal district court complaints.
4. ANDA litigation docket entries.
5. FDA approval dates and first applicant status.
6. Settlement agreements filed with the Federal Trade Commission under applicable reporting requirements.[4-6]

A settlement can delay launch, permit an authorized generic, grant a license, or define an entry date. It should not be inferred from the existence of historical patent litigation alone.

What generic entry risks exist for cyclobenzaprine HCl?

The immediate-release segment has high generic-entry risk. Products compete primarily on acquisition cost, availability, wholesaler coverage, shortage resilience, and contract pricing.

The extended-release segment has more technical barriers because bioequivalence and release control are more demanding. Risk factors include:

• Multiple approved generic manufacturers
• Price compression
• Substitution by immediate-release tablets
• Payer preference for low-cost alternatives
• Limited willingness to pay for modest convenience gains
• Manufacturing variability in coated multiparticulates
• Potential failure of food-effect or alcohol dose-dumping studies

A differentiated product needs a clear commercial reason to exist. Once-daily dosing alone may not justify a premium if generic extended-release products are available. A stronger proposition would combine adherence improvement with lower sedation, improved swallowing, or a delivery format for a defined patient population.

How does cyclobenzaprine compare with competing muscle relaxants?

Cyclobenzaprine competes with methocarbamol, tizanidine, baclofen, carisoprodol, metaxalone, and other centrally acting muscle relaxants. The competitive position depends on dose frequency, sedation, abuse concerns, interaction profile, and payer pricing.

Drug	Common commercial advantage	Formulation opportunity
Cyclobenzaprine	Broad familiarity and generic availability	ODT, liquid, ER, taste-masked products
Methocarbamol	Multiple strengths and established generic use	Lower-pill-burden regimens
Tizanidine	Shorter-acting flexibility	Modified release and adherence products
Baclofen	Established use in spasticity	Controlled delivery and liquid dosing
Metaxalone	Perceived tolerability positioning	Cost-effective reformulation
Carisoprodol	Rapid onset in some use cases	Abuse-deterrent and controlled dispensing

Cyclobenzaprine's commercial weakness is its sedating and anticholinergic profile. Excipient engineering cannot remove those pharmacologic risks. It can, however, improve administration and pharmacokinetic consistency.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve formulation platforms than the active ingredient itself. Attractive partnership structures include:

• Regional licensing of an extended-release or ODT product
• Contract development and manufacturing for multiparticulate capsules
• In-licensing of taste-masking technology
• Co-development with a generic manufacturer
• Authorized-generic supply agreements
• Private-label products for pharmacy and institutional channels
• Combination products with physical therapy adherence programs

A licensee should prioritize ownership of formulation patents, freedom-to-operate in the United States and major foreign markets, demonstrated scale-up data, and a defined regulatory pathway. A formulation patent without bioequivalence feasibility has limited transaction value.

What manufacturing and intellectual-property barriers matter most?

The principal manufacturing barriers are manageable but can affect margins:

• Low-dose blend uniformity
• Segregation during tablet compression
• Coating uniformity for extended-release pellets
• Moisture sensitivity of tablets and polymer coatings
• Content uniformity after scale-up
• Dissolution drift during storage
• Reproducible taste masking
• Packaging compatibility and humidity control

Geographic protection should be assessed separately. U.S. patent coverage, European patent coverage, and rights in regulated generic markets may differ materially. Formulation patents often have narrower claim scope than composition patents and may be easier to design around through changes in polymer grade, coating weight, pellet architecture, or manufacturing sequence.

Key Takeaways

• Cyclobenzaprine HCl is a mature genericized molecule with limited value in conventional immediate-release tablets.
• The strongest excipient opportunities are ODTs, taste-masked liquids, sprinkle capsules, and extended-release multiparticulates.
• Immediate-release products face substantial price and substitution pressure.
• Extended-release products offer more technical differentiation but require stronger bioequivalence and manufacturing controls.
• The original active-ingredient protection has expired; current IP value depends on formulation, manufacturing, and method-of-use claims.
• Cyclobenzaprine's sedation, anticholinergic effects, and interaction warnings cannot be solved through excipient selection.
• Commercial success requires a defined patient or payer benefit, not simply a new excipient combination.
• The most defensible platform is a formulation with measurable pharmacokinetic, administration, or adherence advantages and a manufacturable patent position.

FAQs

Can cyclobenzaprine HCl be formulated as an orally disintegrating tablet?

Yes. An ODT is technically feasible, but taste masking is the central development issue. Mannitol, crospovidone, polymer-coated drug particles, and sweetener systems can support rapid disintegration while limiting bitterness.

Is cyclobenzaprine HCl suitable for a pediatric liquid?

The molecule is not generally positioned for routine pediatric use. A liquid formulation would require a separate safety and labeling strategy, even if the excipient system supports accurate dosing.

What is the best excipient for extended-release cyclobenzaprine?

No single excipient is optimal. Hypromellose, ethylcellulose, and methacrylate polymers can each support extended release, but performance depends on drug loading, particle size, coating weight, pore formation, and gastrointestinal conditions.

Can a new cyclobenzaprine formulation receive 505(b)(2) approval?

Potentially. A materially differentiated dosage form may qualify for a 505(b)(2) pathway if the applicant can rely partly on existing FDA findings while establishing the safety, pharmacokinetic, or clinical attributes of the new product.

Does cyclobenzaprine have biosimilar risk?

No. Cyclobenzaprine HCl is a synthetic small molecule, not a biologic. Competitive risk comes from generic ANDAs, formulation patents, price erosion, and therapeutic substitution rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2023). Cyclobenzaprine hydrochloride tablet prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2023). Amrix and cyclobenzaprine hydrochloride extended-release capsule prescribing information. FDA-approved labeling.

3. National Library of Medicine. (2024). DailyMed: Cyclobenzaprine hydrochloride product labels. U.S. National Library of Medicine.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

6. Federal Trade Commission. (2024). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act. Federal Trade Commission.